DRUGSCAN® and PinneyAssociates to Present Research on Vaping of Abuse-Deterrent Opioids at the PAINWeek Medical Conference

HORSHAM, Pa., Sept. 4, 2018 /PRNewswire/ -- Pharmaceutical companies developing abuse-deterrent formulations may be able to assess a formulation's ability to resist vaping, according to results of an in vitro vaping study conducted by DRUGSCAN® Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, and PinneyAssociates, leading experts in the evaluation of abuse-deterrent formulations. The results will be presented at PAINWeek 2018.

"Although e-cigarettes are not designed with the intent to administer opioid drug products, the success of newer e-cigarette brands and technologies in administering alternative cannabis forms such as herbal, wax and concentrates, indicates other material forms, like ground opioid formulations, might be possible" said Anthony Costantino, PhD, F-ABFT, president of DRUGSCAN® and co-author of the study. "This in vitro model holds promise for pharmaceutical developers for the creation of safer opioid products that deter these newer methods of abuse."

Prescription opioids are abused by various routes of administration, like snorting or injecting. Inhalation of opioid vapors provides rapid delivery of the drug to the blood and brain, producing a faster and stronger euphoric effect that may result in immediate reinforcing effects that contribute to its abuse potential. Online drug tampering forums mention vaping of marketed opioid formulations; however, the success of such attempts is mostly undetermined.

Christopher Altomare of DRUGSCAN® will present the results at PAINWeek 2018 during the poster session on Thursday, Sept. 6, from 6:30 to 8:30 p.m.

Category 1 Assessment: Vaping of Abuse-Deterrent Opioid Formulations

Authors: Christopher Altomare, BS*, Anthony Costantino, PhD*, August Buchhalter, PhD†, Edward Cone, PhD†,

*DRUGSCAN®, Inc., †PinneyAssociates, Inc.

About DRUGSCAN® Inc.

DRUGSCAN® is an ACM Global Laboratory. DRUGSCAN®'s CAT.one® laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product's strengths and weaknesses to physical and chemical manipulations as well as to support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN® has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world. To learn more about DRUGSCAN® and their CAT.one® capabilities, please visit drugscan.com or call 800.235.4890.

About PinneyAssociates, Inc.

PinneyAssociates is a pharmaceutical and consumer healthcare consulting company that helps clients to reduce their regulatory risk and enhance the commercial value of their life sciences products. PinneyAssociates provides services in the areas of abuse-deterrent drug formulation evaluation, abuse potential assessment, and pharmaceutical risk management, as well as Rx-to-OTC switch services and tobacco harm reduction.  Our scientists are leaders in the Category 1 assessment of abuse-deterrent drugs and formulations, including application of our proprietary ALERRT® instrument .  For more information about PinneyAssociates, please visit www.pinneyassociates.com or call +1.301.718.8440.

SOURCE DRUGSCAN

Related Links

http://www.drugscan.com